Response to eribulin in a patient with metastatic uterine leiomyosarcoma: a case report

Sandra Aliberti, Sara Miano, Francesco Tolomeo, Alessandra Merlini, Massimo Aglietta, Giovanni Grignani

Research output: Contribution to journalArticlepeer-review


We report the case of a 51 year-old patient affected by an advanced uterine leiomyosarcoma treated with eribulin as fourth-line therapy. The patient, with a previous history of leiomyomas of the myometrium, had undergone total hysterectomy for repeated metrorrhagias. After 7 years, metastases in the liver, bone and lung were documented. A fine needle liver biopsy demonstrated leiomyosarcoma metastasis. The patient was treated with first-line doxorubicin chemotherapy; after six cycles, disease progression was observed. A second-line trabectedin chemotherapy and a third-line gemcitabine chemotherapy were performed; no objective responses were seen after two cycles. The patient was then treated with eribulin on the basis of an EORTC Phase II trial showing preliminary activity in uterine leiomyosarcoma. After six cycles, CT scan showed partial remission of liver lesion. Disease progression was observed after nine cycles with eribulin, without severe side effects and preserving a good quality of life.

Original languageEnglish
Pages (from-to)15-19
Number of pages5
JournalFuture oncology (London, England)
Issue number1s
Publication statusPublished - Jan 2020


  • Antineoplastic Agents/administration & dosage
  • Biopsy
  • Bone Marrow/pathology
  • Female
  • Furans/administration & dosage
  • Humans
  • Ketones/administration & dosage
  • Leiomyosarcoma/diagnosis
  • Magnetic Resonance Imaging
  • Middle Aged
  • Neoplasm Metastasis
  • Neoplasm Staging
  • Tomography, X-Ray Computed
  • Treatment Outcome

Fingerprint Dive into the research topics of 'Response to eribulin in a patient with metastatic uterine leiomyosarcoma: a case report'. Together they form a unique fingerprint.

Cite this